Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: implications for the involvement of pirin
Open Access
- 23 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1505000
Abstract
Aim: Overcoming therapy resistance is critical for effective melanoma control. Upregulation of Rho/MRTF signaling in human and mouse melanomas causes resistance to targeted therapies. Inhibition of this pathway by MRTFi, CCG-257081 resensitized resistant melanomas to BRAF and MEK inhibitors. It also prevented the development of resistance to vemurafenib (Vem). Here, we investigate the role of apoptosis and the protein pirin in CCG-257081-mediated suppression of drug resistance.Methods: Using naïve and resistant mouse YUMMER melanoma cells, we studied the effect of the BRAF inhibitor Vem with or without CCG-257081 on real-time growth and apoptosis (activation of caspase, Propidium iodide (PI) staining, and PARP cleavage). The effects of CCG-257081 on proliferation (Ki67) and caspase-3 activation were assessed in resistant YUMMER_R tumors in vivo. Finally, two CCG-257081 enantiomers were tested for pirin binding, inhibition of the Rho/MRTF-mediated activation of ACTA2 gene expression in fibroblasts, and the prevention of Vem resistance development by YUMMER_P cells.Results: Vem reduced growth of parental but not resistant cells, while CCG-257081 inhibited both. The combination was more effective than Vem alone. CCG-257081, but not Vem, induced activation of caspase-3 and -7 in resistant cells and increased PARP cleavage and PI staining. CCG-257081 reduced proliferation and activated caspase-3 in YUMMER_R melanoma tumors. Both CCG-257081 enantiomers robustly suppressed development of Vem-resistant colonies with the S isomer being more potent (1 μM IC50).Conclusion: CCG-257081 appears to target pre-resistant cells and Vem-induced resistant cells through enhanced apoptosis. Inhibition of pirin or the Rho/MRTF pathway can be employed to prevent melanoma resistance.Keywords
All Related Versions
This publication has 68 references indexed in Scilit:
- Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockadeInternational Journal of Cancer, 2024
- Pirin Inhibits FAS‐Mediated Apoptosis to Support Colorectal Cancer SurvivalAdvanced Science, 2023
- Prevention of bleomycin‐induced lung fibrosis via inhibition of the MRTF/SRF transcription pathwayPharmacology Research & Perspectives, 2022
- Non-NAD-like PARP-1 inhibitors in prostate cancer treatmentBiochemical Pharmacology, 2019
- Induction of apoptosis in ovarian cancer cells by miR-493-3p directly targeting AKT2, STK38L, HMGA2, ETS1 and E2F5Cellular and Molecular Life Sciences, 2018
- Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic sclerodermaBioorganic & Medicinal Chemistry Letters, 2017
- Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell ApoptosisThe American Journal of Pathology, 2015
- Pirin down‐regulates the EAF2/U19 protein and alleviates its growth inhibition in prostate cancer cellsThe Prostate, 2013
- Pirin Inhibits Cellular Senescence in Melanocytic CellsThe American Journal of Pathology, 2011
- Rationale for the real‐time and dynamic cell death assays using propidium iodideCytometry Part A, 2010